Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 8/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509374 | 1.00 | PTPN1 (0.53) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL18124300 | 1.00 | PTPN1 (0.53) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL29398092 | 1.00 | PTPN1 (0.53) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL30599288 | 1.00 | PTPN1 (0.53) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL29162457 | 0.91 | PTPN1 (0.50) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL1509413 | 0.90 | PTPN1 (0.49) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL1509411 | 0.90 | PTPN1 (0.49) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL16448118 | 0.89 | PTPN1 (0.48) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL5634343 | 0.88 | PTPN1 (0.43) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL5634348 | 0.88 | PTPN1 (0.43) | PTPN1CTSSCTSKACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | LEE PHARMA LIMITED (IN) | 2019-10-22 | — | — | US | disclosed |
| US-20170348309-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2017-12-07 | — | — | US | disclosed |
| EP-2935205-B1 | AN ENZYMATIC ROUTE FOR THE PREPARATION OF CHIRAL GAMMA-ARYL-BETA-AMINOBUTYRIC ACID DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016110750-A1 | NOVEL PROCESS FOR THE PREPARATION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ENZYME INHIBITOR | LEE PHARMA LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| US-9388188-B2 | Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-12 | — | — | US | disclosed |
| US-9388188-B2 | Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-12 | — | — | US | disclosed |
| US-20160194680-A1 | Enzymatic Route For The Preparation Of Chiral Gamma-Aryl-Beta-Aminobutyric Acid Derivatives | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-07 | — | — | US | disclosed |
| US-20160194680-A1 | Enzymatic Route For The Preparation Of Chiral Gamma-Aryl-Beta-Aminobutyric Acid Derivatives | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-07 | — | — | US | disclosed |
| US-9249109-B2 | Method for preparing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004058266-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004037169-A2 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1412357-A1 | BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004032836-A2 | ANTIDIABETIC BETA-AMINO HETEROCYLCIC DIPEPTIDYL PEPTIDASE INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-6699871-B2 | SUCH AS 7-((3R)-3-AMINO-4-(3,4-DIFLUOROPHENYL)BUTANOYL)-2-(TRIFLUOROMETHYL)-5,6,7,8 -TETRAHYDROIMIDAZO(1,2-A)PYRAZINE DIHYDROCHLORIDE FOR TREATMENT OF INSULIN RESISTANCE DISORDERS | MERCK & CO., INC. | 2004-03-02 | — | — | US | disclosed |
| WO-2004007468-A1 | PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003082817-A2 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030100563-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2003-05-29 | — | — | US | disclosed |
| WO-2003004498-A1 | BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | PTPN1 2811/4885CTSS 702/4885CTSK 820/4885 |
| US-20030100563-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PTPN1 2764/4885CTSS 806/4885CTSK 980/4885 |
| US-20160194680-A1 | Enzymatic Route For The Preparation Of Chiral Gamma-Aryl-Beta-Aminobutyric Acid Derivatives | GABRB1, GABRB2, GABRB3 | PTPN1 3426/4885CTSS 848/4885CTSK 1259/4885 |
| US-10450315-B2 | Process for the preparation of dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor | DPP4, DPP7, DPP3 | PTPN1 961/4885CTSS 549/4885CTSK 526/4885 |
| US-20170348309-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | PTPN1 2811/4885CTSS 702/4885CTSK 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.